Scil Proteins establishes business development organisation in California
To be headed by Garry Merry
Merry has a wealth of experience supporting the business development efforts of several small protein engineering, biopharmaceutical and drug discovery companies in North America, including Sloning Biotechnologies, Isogenica and TerraSep. He has also held senior executive positions at life science companies including Waters, Applied Biosystems and Qiagen.
‘A local presence to interface directly with our customers, collaborators and partners in North America is vital to ensure our continued success and the expansion of our business on a global basis,’ said Frank Ubags, chief operating officer of Scil Proteins. ‘With his background in protein engineering and separations, Garry is ideally positioned to help us achieve our growth objectives.’
Scil Proteins’ Affilin drug discovery platform, which is available for out-licensing to biotechnology and pharmaceutical companies, will continue to be supported out of the company’s headquarters in Halle, Germany. The corporate headquarters will also remain responsible for all other activities related to the company’s CMO business outside the US and Canada.
You may also like
Ingredients
Olon: celebrating 10 years of daptomycin and doubled production capacity
Olon's Daptomycin celebrates its 10th anniversary, and in the very year that marks the first decade of production of this first in a new class of antibiotics that represented a breakthrough in the treatment of skin infections, the leading API supplier group announces the doubling of its production to meet and exceed global demand for the active ingredient
Sustainability
Greener and smarter: positive post-pandemic effects in the laboratory sector
The widespread effects of the COVID-19 pandemic can be seen in almost all businesses globally, but not always negatively. According to a survey conducted by Starlab, improvements can be seen in the laboratory sector